Calcimedica, INC 10-K annual reports

CalciMedica, Inc. filed an amendment to its 2025 Annual Report to provide updated corporate governance and executive compensation disclosures.

CalciMedica's 10-K filing summarizes the company's financial status, clinical trial progress, and future plans, emphasizing its focus on CRAC channel inhibitors for inflammatory diseases.

CalciMedica has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

CalciMedica's 10-K filing outlines the company's capital structure, anti-takeover provisions, and regulatory compliance, highlighting its focus on developing CRAC channel inhibitors.